Abstract 13537: The Difference Between Cystatin C- and Creatinine-Based Kidney Function Assessment is Associated With Clinical Outcomes, Quality of Life and Frailty in Patients With Heart Failure and Reduced Ejection Fraction: Insights From PARADIGM-HF

Alberto PinsinoMatthew R CareyHusain A SyedDouglas L JenningsSumit MohanKoji TakedaYoshifumi NakaGabriel T SayerNir UrielRyan T DemmerPaolo C ColomboMelana YuzefpolskayaColumbia Univ Irving Med Cntr,New York,NYUniv of Minnesota,MN

DOI: https://doi.org/10.1161/circ.146.suppl_1.13537

IF: 37.8

2022-11-01

Circulation

Abstract:Introduction: Discrepancies between cystatin C (CysC)- and serum creatinine (sCr)- estimated glomerular filtration rate (eGFR) may reflect sarcopenia and malnutrition. Among pts with heart failure and reduced ejection fraction (HFrEF) enrolled in PARADIGM-HF (Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Converting-Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in HF), we investigated the difference between eGFRCysC and eGFRsCr and its association with clinical outcomes, quality of life (QoL) and frailty. Methods: Intra-individual differences between eGFRCysC and eGFRsCr (eGFRdiff) were calculated at randomization (n=1,970) and 8-month follow-up (n=1,631). Study outcomes included a composite of cardiovascular (CV) mortality or HF admission, and, separately, CV and all-cause mortality, worsening kidney function, poor QoL and frailty. Worsening HF was defined as outpatient intensification of HF therapy, emergency department visit or HF admission between randomization and 8-month follow-up. Results: At randomization, eGFRdiff was >10 and <-10 ml/min/1.73 m 2 in 25 and 36% of the pts, respectively. More negative values of eGFRdiff were associated with worse outcomes (adjusted hazard ratio per 1-standard deviation [SD]: CV mortality or HF admission 1.20, p=.003; CV mortality 1.37, p<.001; all-cause mortality 1.42, p<.001; worsening kidney function 1.30, p=.066). For each 1-SD decrease in eGFRdiff, the prevalence of poor QoL and frailty increased by 28% and 19%, respectively (p ≤.003). Pts with worsening HF had more marked decline in eGFRCysC than eGFRsCr. As a result, worsening HF was associated with a change in 8-month eGFRdiff by -4.7 ml/min/1.73 m 2 ( Figure ). Conclusions: In HFrEF pts, discrepancies between eGFRCysC and eGFRsCr are common and are associated with clinical outcomes, QoL and frailty. In pts with worsening HF, sCr may underestimate decline in kidney function due to changes in muscle mass and diet.

cardiac & cardiovascular systems,peripheral vascular disease